Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Enough flu to go around

The FDA last week felt it necessary to issue a Public Health Advisory reminding physicians to pay attention to their prescribing practices in patients with influenza, as it appears that physicians may have been overly enthusiastic in their use of recently approved neuraminidase inhibitors Tamiflu oseltamivir and Relenza zanamivir. But the drugs' respective marketers, Hoffmann-La Roche Inc. and Glaxo Wellcome Inc., as well as the two biotech companies that developed the drugs, believe that the agency warning will not affect sales significantly.

"Is there inappropriate prescribing? I'm sure there

Read the full 886 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE